Cell Engager Summit 2019
Cell Engager Summit is organized by Hanson Wade and will be held from Jun 25 - 27, 2019 at Revere Hotel Boston Common, Boston, Massachusetts, United States of America.
The Cell Engager Summit is the only meeting focused on developing multi-specific cell engaging therapies in liquid and solid tumor indications; accelerating early discovery innovation into the clinic.
Overcome safety and toxicity challenges by increasing target specificity and improved cellular trafficking through informed target selection to ensure enhanced efficacy of your cell engager drug.
Discover how to effectively scale complicated manufacturing of multispecific cell engagers to reduce production costs and time whilst ensuring purity and quality of antibodies.
With 22 hours of content, 2 interactive workshops and over 5 hours of networking with key industry leaders, this conference will focus solely on cell engaging drugs and how to tackle key clinical and commercial challenges.
Join us as we unite experts from across large pharma, innovative biotech and solution and service providers to bring to market safe and effective multi-specific immune cell engaging therapies.
The clinical proof of concept and potential of cell engager drugs has led to investments and collaborations exploding in the field of multi-specific cell engaging antibody drugs.
The Cell Engager Summit will address the key challengers hindering multi-specific cell engaging drugs from fulfilling their potential and becoming a mainstream cancer therapy.
Join industry leaders to:
• Discover means to minimize toxicity of cell engagers in order to ensure patient safety
• Overcome the logistical challenges of cell engagers by focusing on dosing regimens and the therapeutic window to develop easily administered drugs
• Assess the limitations of cell engager drugs in solid tumor indications to create an effective design of cell engager drug to overcome the immunosuppressive tumor environment
• Evaluate the impact of construct design and target selection on bioactivity, safety and efficacy
• Discover the future potential of cell engager drugs in combination therapies to achieve maximum therapeutic response
Pre Conference Workshops:
Workshop A: Jun 25, 9:00 am - 12:00 pm
Developing Efficacious T Cell Engager Modalities for Targeting Solid Tumors
T cell engagers targeting solid tumors need to achieve an efficacious exposure at a distant tumor site, while at the same time avoiding toxicities caused by high exposures in normal tissues. In contrast, in hematologic malignancies, T cell engagers generally target tumors cells that are in or close to the circulatory system, making it easier to achieve a tolerated therapeutic dose.
Workshop B: Jun 25, 1:00 pm - 4:00 pm
Analyzing the Importance of Target Selection in Early Cell Engager Development
The choice of target in the cell engager space is paramount. Libraries can aide in the decision-making process to find targets which will have maximum efficacy without compromising safety.
Speakers: Chad May, Maverick Therapeutics, David Poon, Zymeworks, Holger Wesche, Harpoon Therapeutics, Jessica Kirshner, Regeneron Pharmaceuticals, Michael Schmidt, Compass Therapeutics, Omid Vafa, TeneoBio, Pavel Pisa, Crescendo Biologics, Seung Chu, Xencor
Time: 9:00 am to 5:00 pm